These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15371454

  • 1. p38 Mitogen-activated protein kinase regulation of endothelial cell migration depends on urokinase plasminogen activator expression.
    Yu J, Bian D, Mahanivong C, Cheng RK, Zhou W, Huang S.
    J Biol Chem; 2004 Nov 26; 279(48):50446-54. PubMed ID: 15371454
    [Abstract] [Full Text] [Related]

  • 2. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM, Roztocil E, Davies MG.
    J Vasc Surg; 2005 Apr 26; 41(4):672-81. PubMed ID: 15874933
    [Abstract] [Full Text] [Related]

  • 3. Rac1-MKK3-p38-MAPKAPK2 pathway promotes urokinase plasminogen activator mRNA stability in invasive breast cancer cells.
    Han Q, Leng J, Bian D, Mahanivong C, Carpenter KA, Pan ZK, Han J, Huang S.
    J Biol Chem; 2002 Dec 13; 277(50):48379-85. PubMed ID: 12377770
    [Abstract] [Full Text] [Related]

  • 4. Urokinase plasminogen activator/urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity.
    Huang S, New L, Pan Z, Han J, Nemerow GR.
    J Biol Chem; 2000 Apr 21; 275(16):12266-72. PubMed ID: 10766865
    [Abstract] [Full Text] [Related]

  • 5. Hyperglycemia impairs cytotrophoblast function via stress signaling.
    Cawyer CR, Horvat D, Leonard D, Allen SR, Jones RO, Zawieja DC, Kuehl TJ, Uddin MN.
    Am J Obstet Gynecol; 2014 Nov 21; 211(5):541.e1-8. PubMed ID: 24793974
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression.
    Stepanova V, Jayaraman PS, Zaitsev SV, Lebedeva T, Bdeir K, Kershaw R, Holman KR, Parfyonova YV, Semina EV, Beloglazova IB, Tkachuk VA, Cines DB.
    J Biol Chem; 2016 Jul 15; 291(29):15029-45. PubMed ID: 27151212
    [Abstract] [Full Text] [Related]

  • 8. Krüppel-like factor 17 inhibits urokinase plasminogen activator gene expression to suppress cell invasion through the Src/p38/ MAPK signaling pathway in human lung adenocarcionma.
    Cai XD, Che L, Lin JX, Huang S, Li J, Liu XY, Pan XF, Wang QQ, Chen L, Lin MJ, Huang ZH, Ma HM, Wu Y, Liu SM, Zhou YB.
    Oncotarget; 2017 Jun 13; 8(24):38743-38754. PubMed ID: 28454121
    [Abstract] [Full Text] [Related]

  • 9. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway.
    Chou RH, Hsieh SC, Yu YL, Huang MH, Huang YC, Hsieh YH.
    PLoS One; 2013 Jun 13; 8(8):e71983. PubMed ID: 23940799
    [Abstract] [Full Text] [Related]

  • 10. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Jun 13; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
    Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR.
    Int J Oncol; 2007 Aug 13; 31(2):441-9. PubMed ID: 17611702
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR, Beaulieu LM, Carter JC, Church FC.
    Gynecol Oncol; 2007 Feb 13; 104(2):470-9. PubMed ID: 17070899
    [Abstract] [Full Text] [Related]

  • 16. miR-20a represses endothelial cell migration by targeting MKK3 and inhibiting p38 MAP kinase activation in response to VEGF.
    Pin AL, Houle F, Guillonneau M, Paquet ER, Simard MJ, Huot J.
    Angiogenesis; 2012 Dec 13; 15(4):593-608. PubMed ID: 22696064
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase.
    Kocić J, Santibañez JF, Krstić A, Mojsilović S, Ilić V, Bugarski D.
    Int J Biochem Cell Biol; 2013 Feb 13; 45(2):464-75. PubMed ID: 23183001
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.